ID   VRK2_HUMAN              Reviewed;         508 AA.
AC   Q86Y07; B4DKL0; D6W5D4; D6W5D6; Q49AK9; Q53EU9; Q53S39; Q53S77;
AC   Q53TU1; Q86Y08; Q86Y09; Q86Y10; Q86Y11; Q86Y12; Q8IXI5; Q99987;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Serine/threonine-protein kinase VRK2;
DE            EC=2.7.11.1;
DE   AltName: Full=Vaccinia-related kinase 2;
GN   Name=VRK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT VAL-167.
RC   TISSUE=Liver;
RX   PubMed=9344656; DOI=10.1006/geno.1997.4938;
RA   Nezu J., Oku A., Jones M.H., Shimane M.;
RT   "Identification of two novel human putative serine/threonine kinases,
RT   VRK1 and VRK2, with structural similarity to Vaccinia virus B1R
RT   kinase.";
RL   Genomics 45:327-331(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), IDENTIFICATION (ISOFORM 1),
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   AUTOPHOSPHORYLATION, AND VARIANT VAL-167.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2)
RT   isoforms determines their different effect on p53 stability in tumour
RT   cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3; 4 AND 5).
RA   Suriyapperuma S.P., Sarfarazi M.;
RT   "Identification of 6 different isoforms for Vaccinia-related kinase 2
RT   (VRK2) gene.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-167.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=14645249; DOI=10.1074/jbc.M310813200;
RA   Nichols R.J., Traktman P.;
RT   "Characterization of three paralogous members of the Mammalian
RT   vaccinia related kinase family.";
RL   J. Biol. Chem. 279:7934-7946(2004).
RN   [10]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS BHRF1.
RX   PubMed=16963744; DOI=10.1099/vir.0.81953-0;
RA   Li L.Y., Liu M.Y., Shih H.M., Tsai C.H., Chen J.Y.;
RT   "Human cellular protein VRK2 interacts specifically with Epstein-Barr
RT   virus BHRF1, a homologue of Bcl-2, and enhances cell survival.";
RL   J. Gen. Virol. 87:2869-2878(2006).
RN   [11]
RP   FUNCTION.
RX   PubMed=16495336; DOI=10.1091/mbc.E05-12-1179;
RA   Nichols R.J., Wiebe M.S., Traktman P.;
RT   "The vaccinia-related kinases phosphorylate the N' terminus of BAF,
RT   regulating its interaction with DNA and its retention in the
RT   nucleus.";
RL   Mol. Biol. Cell 17:2451-2464(2006).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MAP3K7.
RX   PubMed=17709393; DOI=10.1128/MCB.00025-07;
RA   Blanco S., Santos C., Lazo P.A.;
RT   "Vaccinia-related kinase 2 modulates the stress response to hypoxia
RT   mediated by TAK1.";
RL   Mol. Cell. Biol. 27:7273-7283(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-336, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RAN, AND ENZYME
RP   REGULATION.
RX   PubMed=18617507; DOI=10.1074/mcp.M700586-MCP200;
RA   Sanz-Garcia M., Lopez-Sanchez I., Lazo P.A.;
RT   "Proteomics identification of nuclear Ran GTPase as an inhibitor of
RT   human VRK1 and VRK2 (vaccinia-related kinase) activities.";
RL   Mol. Cell. Proteomics 7:2199-2214(2008).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAPK8IP1; MAPK3K7
RP   AND MAP2K7.
RX   PubMed=18286207; DOI=10.1371/journal.pone.0001660;
RA   Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.;
RT   "Modulation of interleukin-1 transcriptional response by the
RT   interaction between VRK2 and the JIP1 scaffold protein.";
RL   PLoS ONE 3:E1660-E1660(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MAP2K1 AND KSR1, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=20679487; DOI=10.1128/MCB.01581-09;
RA   Fernandez I.F., Blanco S., Lozano J., Lazo P.A.;
RT   "VRK2 inhibits mitogen-activated protein kinase signaling and
RT   inversely correlates with ErbB2 in human breast cancer.";
RL   Mol. Cell. Biol. 30:4687-4697(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-406, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 14-335.
RX   PubMed=19141289; DOI=10.1016/j.str.2008.10.018;
RA   Scheeff E.D., Eswaran J., Bunkoczi G., Knapp S., Manning G.;
RT   "Structure of the pseudokinase VRK3 reveals a degraded catalytic site,
RT   a highly conserved kinase fold, and a putative regulatory binding
RT   site.";
RL   Structure 17:128-138(2009).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-50; MET-157 AND VAL-167.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that regulates several signal
CC       transduction pathways. Isoform 1 modulates the stress response to
CC       hypoxia and cytokines, such as interleukin-1 beta (IL1B) and this
CC       is dependent on its interaction with MAPK8IP1, which assembles
CC       mitogen-activated protein kinase (MAPK) complexes. Inhibition of
CC       signal transmission mediated by the assembly of MAPK8IP1-MAPK
CC       complexes reduces JNK phosphorylation and JUN-dependent
CC       transcription. Phosphorylates 'Thr-18' of p53/TP53, histone H3,
CC       and may also phosphorylate MAPK8IP1. Phosphorylates BANF1 and
CC       disrupts its ability to bind DNA and reduces its binding to LEM
CC       domain-containing proteins. Downregulates the transactivation of
CC       transcription induced by ERBB2, HRAS, BRAF, and MEK1. Blocks the
CC       phosphorylation of ERK in response to ERBB2 and HRAS. Can also
CC       phosphorylate the following substrates that are commonly used to
CC       establish in vitro kinase activity: casein, MBP and histone H2B,
CC       but it is not sure that this is physiologically relevant.
CC   -!- FUNCTION: Isoform 2 phosphorylates 'Thr-18' of p53/TP53, as well
CC       as histone H3. Reduces p53/TP53 ubiquitination by MDM2, promotes
CC       p53/TP53 acetylation by EP300 and thereby increases p53/TP53
CC       stability and activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: RAN inhibits its autophosphorylation and its
CC       ability to phosphorylate histone H3.
CC       {ECO:0000269|PubMed:18617507}.
CC   -!- SUBUNIT: Isoform 1 interacts with MAP3K7, MAP2K7, MAP2K1 and KSR1.
CC       Isoform 1 and isoform 2 interact with RAN and MAPK8IP1. Isoform 1
CC       interacts with Epstein-Barr virus BHRF1; this interaction is
CC       involved in protecting cells from apoptosis.
CC       {ECO:0000269|PubMed:16963744, ECO:0000269|PubMed:17709393,
CC       ECO:0000269|PubMed:18286207, ECO:0000269|PubMed:18617507,
CC       ECO:0000269|PubMed:20679487}.
CC   -!- INTERACTION:
CC       Q07817-1:BCL2L1; NbExp=2; IntAct=EBI-1207633, EBI-287195;
CC       P03182:BHRF1 (xeno); NbExp=7; IntAct=EBI-1207615, EBI-1207659;
CC       Q8IVT5:KSR1; NbExp=4; IntAct=EBI-1207615, EBI-486984;
CC       Q61097:Ksr1 (xeno); NbExp=8; IntAct=EBI-1207633, EBI-1536336;
CC       Q02750:MAP2K1; NbExp=2; IntAct=EBI-1207633, EBI-492564;
CC       Q62073:Map3k7 (xeno); NbExp=3; IntAct=EBI-1207633, EBI-1775345;
CC       Q9WVI9-2:Mapk8ip1 (xeno); NbExp=2; IntAct=EBI-1207636, EBI-288464;
CC       Q13469:NFATC2; NbExp=4; IntAct=EBI-1207636, EBI-716258;
CC       Q60591:Nfatc2 (xeno); NbExp=2; IntAct=EBI-1207633, EBI-643104;
CC       P62826:RAN; NbExp=2; IntAct=EBI-1207649, EBI-286642;
CC       Q8CF89:Tab1 (xeno); NbExp=2; IntAct=EBI-1207633, EBI-1778503;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Endoplasmic reticulum
CC       membrane {ECO:0000305}; Single-pass type IV membrane protein
CC       {ECO:0000305}. Mitochondrion membrane {ECO:0000305}; Single-pass
CC       type IV membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=VRK2A;
CC         IsoId=Q86Y07-1; Sequence=Displayed;
CC       Name=2; Synonyms=VRK2B;
CC         IsoId=Q86Y07-2; Sequence=VSP_008537, VSP_008538;
CC       Name=3;
CC         IsoId=Q86Y07-3; Sequence=VSP_008533;
CC         Note=No experimental confirmation available.;
CC       Name=4; Synonyms=5;
CC         IsoId=Q86Y07-4; Sequence=VSP_008534;
CC       Name=5; Synonyms=6;
CC         IsoId=Q86Y07-5; Sequence=VSP_008535, VSP_008536;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in
CC       various tumor cell lines. Expression of isoform 1 inversely
CC       correlates with ERBB2 in breast carcinomas (at protein level).
CC       Widely expressed. Highly expressed in fetal liver, skeletal
CC       muscle, pancreas, heart, peripheral blood leukocytes and testis.
CC       {ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:20679487,
CC       ECO:0000269|PubMed:9344656}.
CC   -!- PTM: Isoform 1 and isoform 2 are autophosphorylated.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. VRK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD54446.2; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VRK2ID42799ch2p16.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB000450; BAA19109.1; -; mRNA.
DR   EMBL; AJ512204; CAD54446.2; ALT_SEQ; mRNA.
DR   EMBL; AY228367; AAO73047.1; -; mRNA.
DR   EMBL; AY228368; AAO73048.1; -; mRNA.
DR   EMBL; AY228369; AAO73049.1; -; mRNA.
DR   EMBL; AY228370; AAO73050.1; -; mRNA.
DR   EMBL; AY228371; AAO73051.1; -; mRNA.
DR   EMBL; AY228372; AAO73052.1; -; mRNA.
DR   EMBL; AK296611; BAG59222.1; -; mRNA.
DR   EMBL; AK223540; BAD97260.1; -; mRNA.
DR   EMBL; AC007250; AAY15019.1; -; Genomic_DNA.
DR   EMBL; AC068193; AAX93262.1; -; Genomic_DNA.
DR   EMBL; AC073215; AAY14648.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00062.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00064.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00066.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00067.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00068.1; -; Genomic_DNA.
DR   EMBL; BC027854; AAH27854.1; -; mRNA.
DR   CCDS; CCDS1859.1; -. [Q86Y07-1]
DR   CCDS; CCDS46291.1; -. [Q86Y07-5]
DR   CCDS; CCDS46292.1; -. [Q86Y07-3]
DR   RefSeq; NP_001123952.1; NM_001130480.2. [Q86Y07-1]
DR   RefSeq; NP_001123953.1; NM_001130481.2. [Q86Y07-1]
DR   RefSeq; NP_001123954.1; NM_001130482.2. [Q86Y07-3]
DR   RefSeq; NP_001123955.1; NM_001130483.2. [Q86Y07-5]
DR   RefSeq; NP_001275765.1; NM_001288836.1. [Q86Y07-4]
DR   RefSeq; NP_001275766.1; NM_001288837.1. [Q86Y07-1]
DR   RefSeq; NP_001275767.1; NM_001288838.1. [Q86Y07-5]
DR   RefSeq; NP_001275768.1; NM_001288839.1. [Q86Y07-4]
DR   RefSeq; NP_006287.2; NM_006296.6. [Q86Y07-1]
DR   RefSeq; XP_005264597.1; XM_005264540.4. [Q86Y07-1]
DR   RefSeq; XP_006712153.1; XM_006712090.3. [Q86Y07-2]
DR   RefSeq; XP_006712154.1; XM_006712091.3. [Q86Y07-5]
DR   RefSeq; XP_006712155.1; XM_006712092.3. [Q86Y07-4]
DR   RefSeq; XP_006712156.1; XM_006712093.3. [Q86Y07-4]
DR   RefSeq; XP_011531394.1; XM_011533092.2. [Q86Y07-1]
DR   RefSeq; XP_016860347.1; XM_017004858.1. [Q86Y07-2]
DR   RefSeq; XP_016860348.1; XM_017004859.1. [Q86Y07-4]
DR   RefSeq; XP_016860349.1; XM_017004860.1. [Q86Y07-4]
DR   RefSeq; XP_016860350.1; XM_017004861.1. [Q86Y07-4]
DR   RefSeq; XP_016860351.1; XM_017004862.1. [Q86Y07-4]
DR   RefSeq; XP_016860352.1; XM_017004863.1. [Q86Y07-4]
DR   UniGene; Hs.715298; -.
DR   UniGene; Hs.744058; -.
DR   PDB; 2V62; X-ray; 1.70 A; A/B=14-335.
DR   PDB; 5UU1; X-ray; 2.00 A; A=14-335.
DR   PDBsum; 2V62; -.
DR   PDBsum; 5UU1; -.
DR   ProteinModelPortal; Q86Y07; -.
DR   SMR; Q86Y07; -.
DR   BioGrid; 113283; 30.
DR   IntAct; Q86Y07; 29.
DR   MINT; MINT-6597566; -.
DR   STRING; 9606.ENSP00000342381; -.
DR   BindingDB; Q86Y07; -.
DR   ChEMBL; CHEMBL1649059; -.
DR   GuidetoPHARMACOLOGY; 2276; -.
DR   iPTMnet; Q86Y07; -.
DR   PhosphoSitePlus; Q86Y07; -.
DR   BioMuta; VRK2; -.
DR   DMDM; 90116515; -.
DR   EPD; Q86Y07; -.
DR   MaxQB; Q86Y07; -.
DR   PaxDb; Q86Y07; -.
DR   PeptideAtlas; Q86Y07; -.
DR   PRIDE; Q86Y07; -.
DR   DNASU; 7444; -.
DR   Ensembl; ENST00000340157; ENSP00000342381; ENSG00000028116. [Q86Y07-1]
DR   Ensembl; ENST00000412104; ENSP00000404156; ENSG00000028116. [Q86Y07-4]
DR   Ensembl; ENST00000417641; ENSP00000402375; ENSG00000028116. [Q86Y07-5]
DR   Ensembl; ENST00000435505; ENSP00000408002; ENSG00000028116. [Q86Y07-1]
DR   Ensembl; ENST00000440705; ENSP00000398323; ENSG00000028116. [Q86Y07-3]
DR   GeneID; 7444; -.
DR   KEGG; hsa:7444; -.
DR   UCSC; uc002rzo.3; human. [Q86Y07-1]
DR   CTD; 7444; -.
DR   DisGeNET; 7444; -.
DR   GeneCards; VRK2; -.
DR   H-InvDB; HIX0002070; -.
DR   HGNC; HGNC:12719; VRK2.
DR   HPA; CAB046459; -.
DR   HPA; HPA047503; -.
DR   MIM; 602169; gene.
DR   neXtProt; NX_Q86Y07; -.
DR   OpenTargets; ENSG00000028116; -.
DR   PharmGKB; PA37331; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   eggNOG; ENOG410XPGP; LUCA.
DR   GeneTree; ENSGT00850000132311; -.
DR   HOVERGEN; HBG007532; -.
DR   InParanoid; Q86Y07; -.
DR   KO; K08816; -.
DR   OMA; HQDFTSP; -.
DR   OrthoDB; EOG091G05V5; -.
DR   PhylomeDB; Q86Y07; -.
DR   TreeFam; TF106473; -.
DR   Reactome; R-HSA-2993913; Clearance of Nuclear Envelope Membranes from Chromatin.
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope Reformation.
DR   SignaLink; Q86Y07; -.
DR   SIGNOR; Q86Y07; -.
DR   ChiTaRS; VRK2; human.
DR   EvolutionaryTrace; Q86Y07; -.
DR   GeneWiki; VRK2; -.
DR   GenomeRNAi; 7444; -.
DR   PRO; PR:Q86Y07; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000028116; -.
DR   ExpressionAtlas; Q86Y07; baseline and differential.
DR   Genevisible; Q86Y07; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IDA:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:2000659; P:regulation of interleukin-1-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Endoplasmic reticulum; Host-virus interaction; Kinase;
KW   Membrane; Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    508       Serine/threonine-protein kinase VRK2.
FT                                /FTId=PRO_0000086806.
FT   TRANSMEM    487    507       Helical; Anchor for type IV membrane
FT                                protein. {ECO:0000255}.
FT   DOMAIN       29    319       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      35     43       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      397    508       Interaction with MAP3K7.
FT                                {ECO:0000269|PubMed:17709393}.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      61     61       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     336    336       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     406    406       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    118       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_008534.
FT   VAR_SEQ       1     23       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_008533.
FT   VAR_SEQ     395    397       EST -> VEA (in isoform 2).
FT                                {ECO:0000303|PubMed:16704422}.
FT                                /FTId=VSP_008537.
FT   VAR_SEQ     395    396       ES -> FR (in isoform 5).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_008535.
FT   VAR_SEQ     397    508       Missing (in isoform 5).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_008536.
FT   VAR_SEQ     398    508       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:16704422}.
FT                                /FTId=VSP_008538.
FT   VARIANT      50     50       N -> D (in dbSNP:rs34130684).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041293.
FT   VARIANT     157    157       I -> M (in dbSNP:rs35966666).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041294.
FT   VARIANT     167    167       I -> V (in dbSNP:rs1051061).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16704422,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9344656}.
FT                                /FTId=VAR_017095.
FT   VARIANT     211    211       N -> S (in dbSNP:rs36081172).
FT                                /FTId=VAR_051681.
FT   CONFLICT    419    419       K -> E (in Ref. 3; AAO73048/AAO73049/
FT                                AAO73051). {ECO:0000305}.
FT   STRAND       20     22       {ECO:0000244|PDB:2V62}.
FT   STRAND       28     34       {ECO:0000244|PDB:2V62}.
FT   STRAND       43     51       {ECO:0000244|PDB:2V62}.
FT   HELIX        53     55       {ECO:0000244|PDB:2V62}.
FT   STRAND       58     64       {ECO:0000244|PDB:2V62}.
FT   STRAND       65     67       {ECO:0000244|PDB:5UU1}.
FT   HELIX        69     80       {ECO:0000244|PDB:2V62}.
FT   HELIX        83     93       {ECO:0000244|PDB:2V62}.
FT   STRAND      103    113       {ECO:0000244|PDB:2V62}.
FT   STRAND      115    122       {ECO:0000244|PDB:2V62}.
FT   STRAND      124    127       {ECO:0000244|PDB:2V62}.
FT   HELIX       128    131       {ECO:0000244|PDB:2V62}.
FT   HELIX       134    136       {ECO:0000244|PDB:2V62}.
FT   HELIX       140    159       {ECO:0000244|PDB:2V62}.
FT   HELIX       169    171       {ECO:0000244|PDB:2V62}.
FT   STRAND      172    178       {ECO:0000244|PDB:2V62}.
FT   STRAND      181    184       {ECO:0000244|PDB:2V62}.
FT   STRAND      191    194       {ECO:0000244|PDB:2V62}.
FT   HELIX       195    197       {ECO:0000244|PDB:2V62}.
FT   HELIX       206    208       {ECO:0000244|PDB:2V62}.
FT   TURN        214    216       {ECO:0000244|PDB:2V62}.
FT   HELIX       219    223       {ECO:0000244|PDB:2V62}.
FT   HELIX       229    245       {ECO:0000244|PDB:2V62}.
FT   HELIX       251    253       {ECO:0000244|PDB:2V62}.
FT   HELIX       257    269       {ECO:0000244|PDB:2V62}.
FT   TURN        270    272       {ECO:0000244|PDB:2V62}.
FT   HELIX       273    278       {ECO:0000244|PDB:2V62}.
FT   HELIX       286    296       {ECO:0000244|PDB:2V62}.
FT   HELIX       306    313       {ECO:0000244|PDB:2V62}.
SQ   SEQUENCE   508 AA;  58141 MW;  9F3F6FCC9280568F CRC64;
     MPPKRNEKYK LPIPFPEGKV LDDMEGNQWV LGKKIGSGGF GLIYLAFPTN KPEKDARHVV
     KVEYQENGPL FSELKFYQRV AKKDCIKKWI ERKQLDYLGI PLFYGSGLTE FKGRSYRFMV
     MERLGIDLQK ISGQNGTFKK STVLQLGIRM LDVLEYIHEN EYVHGDIKAA NLLLGYKNPD
     QVYLADYGLS YRYCPNGNHK QYQENPRKGH NGTIEFTSLD AHKGVALSRR SDVEILGYCM
     LRWLCGKLPW EQNLKDPVAV QTAKTNLLDE LPQSVLKWAP SGSSCCEIAQ FLVCAHSLAY
     DEKPNYQALK KILNPHGIPL GPLDFSTKGQ SINVHTPNSQ KVDSQKAATK QVNKAHNRLI
     EKKVHSERSA ESCATWKVQK EEKLIGLMNN EAAQESTRRR QKYQESQEPL NEVNSFPQKI
     SYTQFPNSFY EPHQDFTSPD IFKKSRSPSW YKYTSTVSTG ITDLESSTGL WPTISQFTLS
     EETNADVYYY RIIIPVLLML VFLALFFL
//
